# A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

> **NCT02218099** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 55 (actual)

## Conditions studied

- Healthy Subjects
- Pharmacokinetics of ASP8232
- Pharmacodynamics of ASP8232
- Chronic Kidney Disease (CKD)
- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** ASP8232
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02218099
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-16
- **Primary completion:** 2014-09-09
- **Final completion:** 2014-09-09
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02218099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02218099, "A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02218099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*